Jump to Navigation
These Old Letters From Ford Show The Rejected Names For...
FDA approves breakthrough hepatitis C drug
Exclusive: Carlyle readies $3 billion sale of chemical...
Duke of York plays start-up Cupid
Sorkin: Bernanke may taper by year-end
DEAR CFA TEST-TAKERS: Here's The Best Advice I Can...
6 Things To Ponder: Bulls, Bears, Valuations &...
Brazil's debt-ridden OGX oil company to change name
Mandela inspired my life
Technology Leads Week With 5 IPO filings; 5 More Added To Calendar
8 U.S. IPOs Planned For The Week
IPO Preview: Cempra Holdings
2 Life Sciences IPOs Debut Below Target
Caesars Stands Out In A Busy IPO Week With Strong Returns
Trius Therapeutics: The Calm Before The Storm
2012 Biotech IPOs: Age Of The Dreamers?
2 Promising Biopharma Companies To Examine
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Companies That Can Mend The Biotech Market: Stephen Brozak
Cempra's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Cempra Management Discusses Toyama Exclusive Agreement Conference (Transcript)
Cempra's CEO Presents at BARDA Contract Award Conference (Transcript)
Can Cempra Beat The Superbugs?
Cempra's Platform Potentially Worth Billions In Battling Superbugs And MRSA
Cempra's CEO Discusses Q2 2013 Results - Earnings Call Transcript
Cempra's CEO Discusses Q3 2013 Results - Earnings Call Transcript
This Antibiotic Play May Be The Trius Of 2014
Canadian banks deliver record $29-billion profit...
The Best Quotes From Ron Burgundy's...
Create new account
Request new password
Click on the icon to sign in with your social network login or enter your Bullfax.com login
EUR/GBP: 1.1931 USD/EUR: 1.3703 JPY/USD: 102.90
Bullfax.com - Market News & Analysis 2008-2011
Terms & Conditions